PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
DOI 10.15252/emmm.201404792 |Published online 30.12.2014
EMBO Molecular Medicine(2014)emmm.201404792
Review Article: Journal of Nutritional Health & Food Science
Vitamin Deficiency and Tuberculosis: Need for Urgent Clinical Page 1- 6
Up-to-date Literature review current through: Jan 2015. | This topic last updated: Jan 29, 2015.
The strategic plan reflects shared commitments to enhance collaboration between environmental, animal (wildlife and domestic) and human health, and building new One Health workforce capacity through higher institutions of learning. The strategy also outlines interventions to be undertaken by governm...ent institutions and other partners to enhance existing structures and pool together additional resources to prevent and control zoonotic diseases and other events of public health importance. Successful implementation of the strategy will contribute to the realization of vision 2020 by improving public health, food safety and security, and hence significantly improve the socioeconomic status of the people of Rwanda. It is in this regard that we call upon implementing institutions, bilateral and multilateral partners, civil society and the private sector to join us in implementing the One Health strategy in Rwanda.
more
This Roadmap is structured around a results-based framework of outcomes, outputs and deliveraebles, to ensure that WHO maintains appropriate levels of organizational readiness, supports country-level capacity building and preparedness, deploys efficiently and effectively to respond to outbreaks and ...emergencies at national and subnational levels, and engages effectively with partners and stakeholders throughout
more
Leitfaden für Fachpersonen des Gesundheitswesens. Grundlage des vorliegenden Handbuchs sind die aktuellen internationalen Leitlinien zur Diagnose und Behandlung der Tuberkulose.
Die vorliegende gekürzte Fassung ergänzt und aktualisiert das «Handbuch Tuberkulose 2012
No publication year indicated.
This document describes recommended measures for dealing with medical and other staff employed either in patient care or in outbreak control during the 2014 Ebola outbreak.
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Journal of The Association of Physicians of India, Vol. 63 November 2015,, pp.77-96
Euro Surveill. 2015 Mar 26;20(12). pii: 21073.